Abraxane News and Research

RSS
The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Study identifies how chemo drug combination kills pancreatic cancer cells

Study identifies how chemo drug combination kills pancreatic cancer cells

Researchers test nanoscale carbon clusters for cancer chemotherapy

Researchers test nanoscale carbon clusters for cancer chemotherapy

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan fourth quarter total revenue increases 18% to $271.0 million

Survey reveals high interest in Xalkori among medical oncologists

Survey reveals high interest in Xalkori among medical oncologists

Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

Elan's third quarter total revenue increases 17% to $328.5 million

Elan's third quarter total revenue increases 17% to $328.5 million

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Celgene reports second quarter total revenue of $1.18 billion

Celgene reports second quarter total revenue of $1.18 billion

NYU Cancer Institute scientists present new research findings at ASCO 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene, Elan enter settlement and license agreement for ABRAXANE

Celgene, Elan enter settlement and license agreement for ABRAXANE

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene acquires Abraxis BioScience

Celgene acquires Abraxis BioScience

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan